Enliven Therapeutics, INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 15.0% of Enliven Therapeutics Inc.'s common stock as of June 30, 2026.

Polar Capital Holdings Plc has filed a Schedule 13G reporting an 8.46% beneficial ownership stake in Enliven Therapeutics, Inc.

Vestal Point Capital, LP and Ryan Wilder have disclosed a passive 5.4% beneficial ownership stake in Enliven Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates report a 2.8% beneficial ownership stake in Enliven Therapeutics, Inc.

Commodore Capital LP and its principals have reported a 7.7% beneficial ownership stake in Enliven Therapeutics, Inc. as of March 31, 2026.

Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported a beneficial ownership of 8.47% in Enliven Therapeutics, Inc.

A group of Venrock entities and individuals reported a continued beneficial ownership of 5.4% in Enliven Therapeutics, Inc. as of September 30, 2025.

FMR LLC and Abigail P. Johnson have disclosed a combined beneficial ownership of 13.3% of Enliven Therapeutics Inc.'s common stock as of September 30, 2025.

Commodore Capital LP and affiliates report a 9.9% beneficial ownership stake in Enliven Therapeutics, Inc., including common stock and pre-funded warrants.

Fairmount Funds Management LLC and related entities reported a 6.3% beneficial ownership stake in Enliven Therapeutics, Inc. common stock.

Polar Capital Holdings Plc and its affiliates have disclosed a 5.17% passive ownership stake in Enliven Therapeutics, Inc. as of June 30, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Enliven Therapeutics Inc., holding 2,941,395 shares of common stock as of June 30, 2025.

Fairmount Funds Management LLC and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 6.6% in Enliven Therapeutics, Inc.'s common stock as of December 31, 2024.

Polar Capital Holdings Plc and its affiliates have disclosed a beneficial ownership of 4.89% in Enliven Therapeutics, Inc., holding 2,389,668 shares of common stock as of December 31, 2024.